|
|
| | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline Basic information |
| Product Name: | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline | | Synonyms: | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline;Quinoline, 4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-;4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline DMH 1;DMH 1 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;4-[6-(4-Isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;DMH-1, >=98%;4-[6-(4-propan-2-yloxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;DMH-1(VU036482) | | CAS: | 1206711-16-1 | | MF: | C24H20N4O | | MW: | 380.44 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1206711-16-1.mol | ![4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline Structure](CAS/GIF/1206711-16-1.gif) |
| | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline Chemical Properties |
| Melting point | 178 °C | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble5mg/mL, clear (warmed) | | pka | 3.34±0.46(Predicted) | | form | powder | | color | light yellow to orange |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | WGK Germany | 3 | | HS Code | 2933.49.7000 |
| | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline Usage And Synthesis |
| Description | Bone morphogenetic proteins (BMP) are secreted signaling proteins, many of which are involved in various developmental processes, in addition to bone formation. DMH1 is an analog of the non-selective BMP receptor inhibitor dorsomorphin that potently inhibits the kinase activity of activin receptor-like kinase 2 (ALK2; IC50 = 13-108 nM). It is much less effective at ALK4, ALK5, AMPK, KDR (VEGFR2) or PDGFRβ, although it inhibits ALK1 and ALK3 at nanomolar concentrations. DMH1 is effective in vivo, as it disrupts dorsoventral development in zebrafish. It also affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis. DMH1 inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft mouse model. | | Uses | DMH 1 is an inhibitor that exclusively targets the bone morphogenetic protein (BMP) but not the vascular endothelial growth factor (VEGF) pathway. DMH 1 promotes neurogenesis of human-induced pluripotent stem cells (hiPSCs) | | Uses | DMH1 has been used for bone morphogenetic protein (BMP) inhibition. It has also been used to block vascular endothelial growth factor (VEGF) signaling. | | Definition | ChEBI: DMH1 is a pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine bearing quinolin-4-yl and 4-isopropyloxyphenyl substituents at positions 3 and 6 respectively. It has a role as a protein kinase inhibitor, a bone morphogenetic protein receptor antagonist and an antineoplastic agent. It is a member of quinolines, a pyrazolopyrimidine and an aromatic ether. | | General Description | DMH1 stimulates neurogenesis of human-induced pluripotent stem cells (hiPSCs) and suppresses the growth and metastasis of lung cancer. It blocks cellular autophagy responses. | | Biochem/physiol Actions | DMH1 is a highly selective Bone morphogenetic protein (BMP) inhibitor. DMH1 is a dorsomorphin analogue that exclusively targets the BMP but not the VEGF pathway. | | storage | +4°C | | references | [1] hao j, ho j n, lewis j a, et al. in vivo structure- activity relationship study of dorsomorphin analogues identifies selective vegf and bmp inhibitors. acs chemical biology, 2010, 5(2): 245-253.
[2] hao j, lee r, chang a, et al. dmh1, a small molecule inhibitor of bmp type i receptors, suppresses growth and invasion of lung cancer. plos one, 2014, 9(3): e90748. |
| | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline Preparation Products And Raw materials |
|